DK2109622T3 - High affinity antibodies neutralizing staphylococcus enterotoxin B - Google Patents

High affinity antibodies neutralizing staphylococcus enterotoxin B Download PDF

Info

Publication number
DK2109622T3
DK2109622T3 DK08712978.9T DK08712978T DK2109622T3 DK 2109622 T3 DK2109622 T3 DK 2109622T3 DK 08712978 T DK08712978 T DK 08712978T DK 2109622 T3 DK2109622 T3 DK 2109622T3
Authority
DK
Denmark
Prior art keywords
ser
val
leu
gly
thr
Prior art date
Application number
DK08712978.9T
Other languages
Danish (da)
English (en)
Inventor
Philip M Sass
Marc Berger
Tao Sai
Nicholas C Nicolaides
Luigi Grasso
Original Assignee
Morphotek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphotek Inc filed Critical Morphotek Inc
Application granted granted Critical
Publication of DK2109622T3 publication Critical patent/DK2109622T3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK08712978.9T 2007-01-03 2008-01-03 High affinity antibodies neutralizing staphylococcus enterotoxin B DK2109622T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88327107P 2007-01-03 2007-01-03
US88840507P 2007-02-06 2007-02-06
PCT/US2008/000104 WO2008085878A2 (en) 2007-01-03 2008-01-03 High affinity antibodies that neutralize staphylcoccus enterotoxin b

Publications (1)

Publication Number Publication Date
DK2109622T3 true DK2109622T3 (en) 2017-02-13

Family

ID=39529113

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08712978.9T DK2109622T3 (en) 2007-01-03 2008-01-03 High affinity antibodies neutralizing staphylococcus enterotoxin B

Country Status (9)

Country Link
US (6) US8236932B2 (enExample)
EP (2) EP3138852A1 (enExample)
JP (3) JP5412293B2 (enExample)
AU (1) AU2008205376B2 (enExample)
CA (2) CA2924155C (enExample)
DK (1) DK2109622T3 (enExample)
ES (1) ES2619943T3 (enExample)
PL (1) PL2109622T3 (enExample)
WO (1) WO2008085878A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236932B2 (en) 2007-01-03 2012-08-07 Morphotek, Inc. High affinity antibodies that neutralize Staphylococcus enterotoxin B
WO2010030182A2 (en) * 2008-09-10 2010-03-18 Bac Ip B.V. Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases
WO2013089877A2 (en) * 2011-09-27 2013-06-20 Albert Einstein College Of Medicine Of Yeshiva University Adjuvant therapy for staphylococcal infection with enterotoxin specific mabs
SG10201608341XA (en) * 2011-11-23 2016-11-29 Hoffmann La Roche Cd40l expressing mammalian cells and their use
US20160039914A1 (en) * 2013-03-14 2016-02-11 Albert Einstein College Of Medicine Of Yeshiva University Humanized antibodies specific for staphylococcal enterotoxin b
US10995152B2 (en) 2016-10-26 2021-05-04 The Board Of Trustees Of The Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
MX2019005772A (es) * 2016-11-23 2019-10-02 Bioverativ Therapeutics Inc Anticuerpos mono y biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x.
KR102124258B1 (ko) * 2018-10-19 2020-06-26 대한민국(관리부서 질병관리본부장) 신속 면역크로마토그래피법을 이용한 황색 포도알균 장독소 b 진단·탐지 키트 및 이를 위한 특이항체와 항체생산세포주
JP7716399B2 (ja) * 2019-11-01 2025-07-31 ブイオーアール バイオファーマ インコーポレーテッド 抗-cd45抗体及びそのコンジュゲート
KR102274759B1 (ko) * 2020-01-16 2021-07-09 대한민국(질병관리청장) 황색포도알균 장독소 b에 특이적인 항체 및 이의 용도
CN119101153B (zh) * 2024-04-30 2025-07-08 中国人民解放军军事科学院军事医学研究院 一种葡萄球菌肠毒素b纳米抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2574089A (en) 1948-06-08 1951-11-06 Cochran Jacqueline Luggage case having a removable lining
US4854432A (en) 1988-07-06 1989-08-08 American Tourister, Inc. Suitcase having removable divider with clothing pockets
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
CA2194450A1 (en) 1994-07-06 1996-01-18 Truckin' Movers Corporation Convertible carrying case and work platform
US6036697A (en) 1998-07-09 2000-03-14 Scimed Life Systems, Inc. Balloon catheter with balloon inflation at distal end of balloon
WO2000020598A1 (en) 1998-10-07 2000-04-13 The Rockefeller University Peptides useful for reducing symptoms of toxic shock syndrome and septic shock
US8420353B2 (en) 2002-03-22 2013-04-16 Aprogen, Inc. Humanized antibody and process for preparing same
CA2496242A1 (en) 2002-08-21 2004-03-04 Merck Patent Gesellschaft Mit Beschraenkter Haftung T-cell epitopes in staphylococcal enterotoxin b
JP4571586B2 (ja) * 2003-09-05 2010-10-27 一般財団法人化学及血清療法研究所 プロテアーゼ耐性seb改変体およびそれを含むワクチン
CN101155832B (zh) * 2005-02-08 2013-02-06 一般财团法人化学及血清疗法研究所 抗体的改良方法
EA018030B1 (ru) * 2006-06-06 2013-05-30 Круселл Холланд Б.В. Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
US8236932B2 (en) * 2007-01-03 2012-08-07 Morphotek, Inc. High affinity antibodies that neutralize Staphylococcus enterotoxin B

Also Published As

Publication number Publication date
CA2674382C (en) 2016-05-31
CA2924155C (en) 2020-02-11
JP2016146824A (ja) 2016-08-18
US9359428B2 (en) 2016-06-07
CA2674382A1 (en) 2008-07-17
EP2109622A2 (en) 2009-10-21
PL2109622T3 (pl) 2017-06-30
JP5881646B2 (ja) 2016-03-09
ES2619943T3 (es) 2017-06-27
US8895704B2 (en) 2014-11-25
AU2008205376A1 (en) 2008-07-17
US10364284B2 (en) 2019-07-30
EP2109622B1 (en) 2016-11-09
US20180094048A1 (en) 2018-04-05
US8236932B2 (en) 2012-08-07
JP6195946B2 (ja) 2017-09-13
CA2924155A1 (en) 2008-07-17
JP2010514459A (ja) 2010-05-06
US20150050276A1 (en) 2015-02-19
US20130183314A1 (en) 2013-07-18
EP3138852A1 (en) 2017-03-08
US20120171223A1 (en) 2012-07-05
JP2013216673A (ja) 2013-10-24
JP5412293B2 (ja) 2014-02-12
US8889846B2 (en) 2014-11-18
US20170121396A1 (en) 2017-05-04
AU2008205376B2 (en) 2012-07-12
US9868780B2 (en) 2018-01-16
US20140072553A1 (en) 2014-03-13
WO2008085878A2 (en) 2008-07-17
WO2008085878A3 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
AU2020203853C1 (en) Human immunodeficiency virus (HIV)-neutralizing antibodies
DK2109622T3 (en) High affinity antibodies neutralizing staphylococcus enterotoxin B
KR102831970B1 (ko) 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
KR20220167273A (ko) 항-코로나바이러스 항체 및 사용 방법
CN110869389B (zh) 抗ror1抗体及其制备和使用方法
AU2015292406B2 (en) Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
CN111954680B (zh) IL2Rβ/共同γ链抗体
TWI891060B (zh) 編碼胃抑肽受體(gipr)特異性抗體之核酸分子及製造該抗體之方法
KR102096224B1 (ko) 폴리펩티드 구축물 및 이의 용도
AU2023204017A1 (en) Human immunodeficiency virus (HIV) -neutralizing antibodies
KR20210050547A (ko) 항-클라우딘18.2 항체 및 이의 용도
CN114106183A (zh) 抗cld18a2纳米抗体及其应用
KR20190133160A (ko) 항-gprc5d 항체 및 항-gprc5d 항체를 포함하는 분자
KR20220040483A (ko) 칼리크레인 관련 펩티다제 2 항원 결합 도메인을 포함하는 단백질 및 이의 용도
KR20170040249A (ko) 항-cdh6 항체 약물 접합체
KR20180063336A (ko) Hiv 감염의 예방 또는 치료를 위한 3특이성 및/또는 3가 결합 단백질
KR20150006471A (ko) 항-pcsk9 항체 및 그의 용도
KR20190101435A (ko) 에스. 아우레우스 용혈소 a 독소에 대한 인간 항체
KR20230017841A (ko) Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도
KR20230142482A (ko) 칼리크레인 관련 펩티다제 2 항원 결합 도메인을 포함하는면역접합체 및 이의 용도
AU2019261450B2 (en) Human-derived anti-(poly-GA) dipeptide repeat (DPR) antibody
KR20160021849A (ko) 렉틴-유사 산화된 ldl 수용체1 항체 및 사용 방법
KR20220154710A (ko) 소형 유도 및 항법 제어(miniGNC) 항체-유사 단백질 및 이의 제조 및 사용 방법
KR20230137393A (ko) Psma 결합 단백질 및 이의 용도
KR20230059789A (ko) 항-가변 muc1* 항체 및 이의 용도